Effect of Theophylline in Pseudohypoparathyroidism
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT03718403
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- PHP IB
- PHP Ia
- Php1C
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Theophylline — DRUGTheophylline will be given to maintain a peak level between 10-15 mcg/mL
Study Details
The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism.
Key Dates
- Start date
- Nov 11, 2019
- Status verified
- Jul 2022
- Primary completion
- Apr 10, 2030
- Completion
- Apr 10, 2032
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Single arm open labeled intervention studySubjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
Primary Outcome Measure
Effect of Theophylline on Bone Age in PHP [ Time Frame: 52 weeks ]
Central Contacts
- AMITA SHARMA, MD6177262908
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 |
Find similar trials in Boston, MA
By research site